Advanced

Use of calcium channel blockers as antihypertensives in relation to mortality and cancer incidence: a population-based observational study

Lindberg, Gunnar LU ; Lindblad, Ulf LU ; Löw-Larsen, Bent; Merlo, Juan LU ; Melander, Arne LU and Råstam, Lennart LU (2002) In Pharmacoepidemiology and Drug Safety 11(6). p.493-497
Abstract
Abstract



Purpose

Treatment with blood pressure lowering drugs may reduce morbidity and mortality. However, the efficacy and effectiveness may differ between antihypertensive agents. The current investigation aimed to compare mortality and cancer incidence in hypertensive patients treated with calcium channel blockers (CCB) or with other antihypertensive drugs (AHD).



Methods

All patients in two outpatient clinics treated with AHD who underwent an annual check-up during 1989 or 1990 were selected. Fatal events were identified through 1997 and incident cancers through 1998.



Results

Two hundred and fourteen patients on CCB and 1029 on other AHD were identified.... (More)
Abstract



Purpose

Treatment with blood pressure lowering drugs may reduce morbidity and mortality. However, the efficacy and effectiveness may differ between antihypertensive agents. The current investigation aimed to compare mortality and cancer incidence in hypertensive patients treated with calcium channel blockers (CCB) or with other antihypertensive drugs (AHD).



Methods

All patients in two outpatient clinics treated with AHD who underwent an annual check-up during 1989 or 1990 were selected. Fatal events were identified through 1997 and incident cancers through 1998.



Results

Two hundred and fourteen patients on CCB and 1029 on other AHD were identified. Overall mortality and the combined mortality from myocardial infarction and stroke were higher in CCB users; hazard ratios adjusted for sex, age, co-morbidity and other and risk factors were 1.84 (95% CI 1.25-2.72) and 2.37 (95% CI 1.27-4.44), respectively. The risk estimates for cancer mortality and for cancer incidence did not differ significantly.



Conclusions

Results from clinical trials as well as observational studies, including the present one, indicate a higher mortality risk and a higher cardiovascular morbidity risk associated with use of CCB. Accordingly, CCB should not be regarded as first line drugs in hypertension. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Pharmacoepidemiology and Drug Safety
volume
11
issue
6
pages
493 - 497
publisher
John Wiley & Sons
external identifiers
  • WOS:000178751100009
  • PMID:12426934
  • Scopus:0036750064
ISSN
1053-8569
DOI
10.1002/pds.737
language
English
LU publication?
yes
id
b8d15ae3-e4d1-4087-ba3f-d4dbf0134b69 (old id 123260)
date added to LUP
2007-07-25 14:25:50
date last changed
2017-01-01 07:57:31
@article{b8d15ae3-e4d1-4087-ba3f-d4dbf0134b69,
  abstract     = {Abstract<br/><br>
<br/><br>
Purpose<br/><br>
Treatment with blood pressure lowering drugs may reduce morbidity and mortality. However, the efficacy and effectiveness may differ between antihypertensive agents. The current investigation aimed to compare mortality and cancer incidence in hypertensive patients treated with calcium channel blockers (CCB) or with other antihypertensive drugs (AHD).<br/><br>
<br/><br>
Methods<br/><br>
All patients in two outpatient clinics treated with AHD who underwent an annual check-up during 1989 or 1990 were selected. Fatal events were identified through 1997 and incident cancers through 1998.<br/><br>
<br/><br>
Results<br/><br>
Two hundred and fourteen patients on CCB and 1029 on other AHD were identified. Overall mortality and the combined mortality from myocardial infarction and stroke were higher in CCB users; hazard ratios adjusted for sex, age, co-morbidity and other and risk factors were 1.84 (95% CI 1.25-2.72) and 2.37 (95% CI 1.27-4.44), respectively. The risk estimates for cancer mortality and for cancer incidence did not differ significantly.<br/><br>
<br/><br>
Conclusions<br/><br>
Results from clinical trials as well as observational studies, including the present one, indicate a higher mortality risk and a higher cardiovascular morbidity risk associated with use of CCB. Accordingly, CCB should not be regarded as first line drugs in hypertension.},
  author       = {Lindberg, Gunnar and Lindblad, Ulf and Löw-Larsen, Bent and Merlo, Juan and Melander, Arne and Råstam, Lennart},
  issn         = {1053-8569},
  language     = {eng},
  number       = {6},
  pages        = {493--497},
  publisher    = {John Wiley & Sons},
  series       = {Pharmacoepidemiology and Drug Safety},
  title        = {Use of calcium channel blockers as antihypertensives in relation to mortality and cancer incidence: a population-based observational study},
  url          = {http://dx.doi.org/10.1002/pds.737},
  volume       = {11},
  year         = {2002},
}